Abstract
Fungal endophthalmitis is a rare but serious infection. In March 2012, several cases of probable and laboratoryconfirmed fungal endophthalmitis occurring after invasive ocular procedures were reported nationwide. We identified 47 cases in 9 states: 21 patients had been exposed to the intraocular dye Brilliant Blue G (BBG) during retinal surgery, and the other 26 had received an intravitreal injection containing triamcinolone acetonide. Both drugs were produced by Franck's Compounding Lab (Ocala, FL, USA). Fusarium incarnatum-equiseti species complex mold was identified in specimens from BBG-exposed case-patients and an unopened BBG vial. Bipolaris hawaiiensis mold was identified in specimens from triamcinolone-exposed case-patients. Exposure to either product was the only factor associated with case status. Of 40 case-patients for whom data were available, 39 (98%) lost vision. These concurrent outbreaks, associated with 1 compounding pharmacy, resulted in a product recall. Ensuring safety and integrity of compounded medications is critical for preventing further outbreaks associated with compounded products.
Cite
CITATION STYLE
Mikosz, C. A., Smith, R. M., Kim, M., Tyson, C., Lee, E. H., Adams, E., … Park, B. J. (2014). Fungal endophthalmitis associated with compounded products. Emerging Infectious Diseases, 20(2), 248–256. https://doi.org/10.3201/eid2002.131257
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.